Schenkein David P 4

What Happened

• David P. Schenkein, a director of Denali Therapeutics (DNLI), received equity awards on 2026-06-03: 6,408 restricted stock units (RSUs) and 19,226 derivative RSU-type awards. The Form 4 reports $0 as the transaction price/value (these were compensatory awards, not open-market purchases).

Key Details

• Transaction date: June 3, 2026; Form 4 filed June 5, 2026 (timely filing).
• Reported price/value: $0 for both items (standard for many RSU/derivative grants on Form 4).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting: Footnotes state 100% of the RSUs (and shares subject to an option, where applicable) vest upon the earlier of (i) one year after the grant or (ii) the day before the issuer’s next annual meeting of stockholders.
• Trust holdings: Some shares are held of record by the David P. Schenkein 2004 Revocable Trust and the Amy P. Schenkein 2004 Revocable Trust (he and his spouse serve as trustees) — these reflect record ownership reported on the form.
• No 10b5-1 plan, tax-withholding sale, or late-filing indication provided in the excerpt.

Context

• These are compensatory awards (RSUs/contingent rights) that do not represent immediately tradable shares. They convert to common stock only upon vesting according to the schedule noted above. Such awards are routine for directors and reflect compensation rather than an open-market purchase or sale.